Sofantinib is a targeted drug with anti-angiogenic as well as immunomodulatory properties and is commonly used in the treatment of pancreatic neuroendocrine tumors.
Sofantinib is a novel oral tyrosine kinase inhibitor with a unique synergistic anti-tumor mechanism. Sofentinib has both “anti-angiogenic” and “immunomodulatory” activities, which can prevent the generation of new blood vessels in the tumor by inhibiting VEGF receptor and FGF receptor.
It can also inhibit colony-stimulating factor-1 receptor to regulate macrophages, improve the immune microenvironment, and activate human immune function.
Sofantinib monotherapy is indicated for inoperable locally advanced or metastatic, progressive non-functional, well-differentiated (G1, G2) pancreatic and non-pancreatic-derived neuroendocrine tumors. Patients may experience adverse reactions such as proteinuria, hypertension, elevated blood bilirubin, and diarrhea during the use of the drug; in addition, it is contraindicated in patients with severe hepatic insufficiency, pregnancy, and severe active bleeding.
The drug should be used under the guidance of a doctor.